Related references
Note: Only part of the references are listed.Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
Stergios Boussios et al.
INVESTIGATIONAL NEW DRUGS (2020)
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Richard T. Penson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Andres Poveda et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Population-adjusted indirect treatment comparison (PAITC) of maintenance PARP inhibitor (PARPi) with or without bevacizumab versus bevacizumab in women with newly diagnosed ovarian cancer (OC).
Robert Hettle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Stergios Boussios et al.
DRUGS IN R&D (2020)
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann et al.
LANCET ONCOLOGY (2020)
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
William P. Tew et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Wise Management of Ovarian Cancer: On the Cutting Edge
Stergios Boussios et al.
JOURNAL OF PERSONALIZED MEDICINE (2020)
The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination
Weixing Zhao et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88 (2019)
PARP inhibitors in ovarian cancer
Elisena Franzese et al.
CANCER TREATMENT REVIEWS (2019)
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore et al.
LANCET ONCOLOGY (2019)
Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21
Dae-Seok Kim et al.
MOLECULAR CELL (2019)
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Stergios Boussios et al.
DIAGNOSTICS (2019)
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Deborah K. Armstrong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey
Panagiotis A. Konstantinopoulos et al.
CLINICAL CANCER RESEARCH (2018)
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Heidi J. Gray et al.
GYNECOLOGIC ONCOLOGY (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
The Era of PARP inhibitors in ovarian cancer: Class Action or not? A systematic review and meta-analysis
Nicoletta Staropoli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
Renata Rodrigues da Cunha Colombo Bonadio et al.
CLINICS (2018)
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer
Katherine C. Kurnit et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2017)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza et al.
GYNECOLOGIC ONCOLOGY (2017)
Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer A Phase I/II Study
Karina Dahl Steffensen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Repair, Reuse, Recycle: The Expanding Role of Autophagy in Genome Maintenance
Graeme Hewitt et al.
TRENDS IN CELL BIOLOGY (2017)
Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age
Xuan Jiang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2017)
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Akihiro Ohmoto et al.
ONCOTARGETS AND THERAPY (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
Mallika S. Dhawan et al.
CLINICAL CANCER RESEARCH (2017)
Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
Shin Nishio et al.
CANCER SCIENCE (2017)
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors
Tadaaki Nishikawa et al.
CANCER SCIENCE (2017)
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit et al.
CLINICAL CANCER RESEARCH (2017)
Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study
H. S. Han et al.
CANCER RESEARCH (2017)
Pathogenesis and heterogeneity of ovarian cancer
Paul T. Kroeger et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2017)
The Dualistic Model of Ovarian Carcinogenesis Revisited, Revised, and Expanded
Robert J. Kurman et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2016)
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Alexi A. Wright et al.
GYNECOLOGIC ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2015)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Clare L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer
Theresa A. Lawrie et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
Saul E. Rivkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2
Ashok R. Venkitaraman
SCIENCE (2014)
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
Johnathan A. Watkins et al.
BREAST CANCER RESEARCH (2014)
Final results of a phase 1 study of single-agent veliparib (V) in patients (pis) with either BRCA1/2-mutated cancer (BRCA plus ), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).
Shannon Puhalla et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2013)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2012)
Current Surgical Management of Ovarian Cancer
John O. Schorge et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Bryan A. Gibson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer
Jo Morrison et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
Shiyu Zhang et al.
GYNECOLOGIC ONCOLOGY (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Ovarian carcinoma pathology and genetics: recent advances
C. Blake Gilks et al.
HUMAN PATHOLOGY (2009)
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
Cherrie K. Donawho et al.
CLINICAL CANCER RESEARCH (2007)